関連ニュース

Kyverna Therapeutics, Inc. (KYTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Kyverna Therapeutics remains a 'Strong Buy' as miv-cel advances in SPS, gMG, and refractory RA with robust clinical data. Rolling BLA submission for miv-cel in SPS is underway, targeting completion by